Ainhoa Madariaga

EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

Stéphanie Lheureux, Ana Oaknin, Swati Garg et al. · Clinical Cancer Research · 2020 · 126 citations · Full text

A cost-analysis of suspected adverse drug reactions in a hospital emergency ward

I. Ayani, C Aguirre, Garazi Gutiérrez et al. · Pharmacoepidemiology and Drug Safety · 1999 · 32 citations

Diagnosis, Hospital Emergency Ward, Emergency Care +18

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield et al. · Clinical Cancer Research · 2023 · 28 citations · Full text

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma

Ainhoa Madariaga, Swati Garg, Naïri Tchrakian et al. · Nature Communications · 2023 · 25 citations · Full text

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

Jitendra PS. Sawhney, V A Kothiwale, Vikas Bisne et al. · Indian Heart Journal · 2018 · 21 citations · Full text